Whalesbook
Legal Framework Guides Emerging Market
India's burgeoning medical cannabis industry is navigating a complex legal path, focusing on plant parts deemed legal under the Narcotic Drugs and Psychotropic Substances Act. While cannabis flowers and resin remain prohibited, companies leverage seeds, leaves, and fiber, extracting compounds like CBD (cannabidiol) and strictly controlled, minimal amounts of THC (tetrahydrocannabinol). This has allowed a new generation of entrepreneurs to establish ventures such as Qurist and Bombay Hemp Company (Boheco), which offer products for chronic pain, anxiety, sleep disorders, and even pet ailments.
Product Diversification and Patient Access
These companies are developing a wide array of products, from oils and tinctures to capsules and edibles, catering to diverse patient needs. Oils, commonly priced between ₹1,500 to ₹12,000 depending on potency, are a popular choice for managing pain, stress, and sleep. Capsules and edibles offer convenience and precise dosing, ranging from under ₹500 for low-dose packs to over ₹8,000 for higher-dosage bottles. Sales occur through both online channels, involving doctor consultations within 24 hours, and physical retail outlets, such as Cure By Design's stores, promoting accessible, judgment-free patient education.
Entrepreneurial Ambitions and Global Outlook
Founders like Samisht Sehgal of Qurist and Yash Kotak of Boheco highlight a growing consumer trust in plant-based medicine and strong repeat usage. Abhishek Mohan of HempStreet is even using India as an R&D base for developing cannabis treatments aimed at international markets, with launches planned in the US and approvals sought in Brazil and Thailand. This strategic approach aims to modernize Ayurveda and position Indian medicinal products on the global stage, demonstrating a shift from lifestyle applications to precision medicine.
Challenges and Legitimacy Push
Despite rapid momentum, the medical cannabis sector faces hurdles, including difficulty in securing funding as many investors remain wary. Companies emphasize their commitment to legitimacy, operating within regulatory frameworks, paying Goods and Services Tax (GST), and collaborating with banks. Ratan Tata's early investment in Boheco signifies growing confidence. As revenue streams double or triple for companies like Qurist, the industry is steadily moving from the fringe towards mainstream healthcare, offering tangible relief to patients suffering from chronic conditions.